Trusted Resources: News & Meetings
Latest announcements and gatherings
Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 Study
Results from the phase 3 OPTIC study showed more patients treated with teprotumumab had a meaningful improvement in proptosis compared with those who received placebo.
The confirmatory trial evaluated teprotumumab for the treatment of active thyroid eye disease.
The primary endpoint of the study was met, with 82.9% of 41 teprotumumab-treated patients achieving a 2 mm or more reduction of proptosis compared with 9.5% of 42 placebo patients, a statically significant difference (P < .001), according to a press release from Horizon Pharma.
All secondary endpoints were met in the study. A greater percentage of teprotumumab-treated patients experienced a 2 point or greater reduction in clinical activity score and a 2 mm or greater reduction in proptosis from baseline, with no deterioration in clinical activity score or proptosis in the fellow eye, compared with the placebo group.
myBinderRelated Content
-
Catherine J. Hwang, MDDr. Catherine J. Hwang was born in New Y...
-
Anthony Maloof, MBBS hons, MBiomedE, FRANZCODr. Maloof is an internationally recogni...
-
Quality of Life Remains Poor in People With Thyroid Eye Diseasehttps://www.youtube.com/watch?v=fwYlJ_pt...
-
Efficacy of B-cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves’ Orbitopa...Background: Preliminary studies have sh...
-
TED and Smoking: Information for PatientsHyperthyroidism is a condition where the...
-
New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
-
A New Era in the Treatment of Thyroid Eye DiseasePurpose: Improved understanding of thyr...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google